Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical') today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty Clinic, a clinic operated under the management support of SBC Medical Group, a consolidated subsidiary, presented their research findings at 'The 113th Congress of Japan Society of Aesthetic Surgery.'
Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated
The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field.
Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress
At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration.
Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group
Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group
In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice.
The 113th Congress of Japan Society of Aesthetic SurgeryVenue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 Official website：https://square.umin.ac.jp/jsas113/index.html
Presentation Topics
Chair / Speaker
Job Title
Title
Yoshiyuki Aikawa
CEO, SBC Medical Group Holdings
【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing【Special Lecture/Chair】The future of cosmetic medicine and AI
Daisuke Nakamura
Chief Medical Director of Shonan Beauty Group, Chief of Breast Augmentation at SBC
【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation
Kazuhiro Igawa
Representative Assistant and Technical Advisor, Shonan Beauty Group
【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts
Ayaka Nishikawa
Director of Dermatology Department of Shonan Beauty Group
【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management 【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution 【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF 【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector? 【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins 【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment
Jiro Kataoka
Area Medical Director and Anti-Aging Expert Doctor
【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~ 【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes
Shoko Takahashi
Top expert doctor in rejuvenation
【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting
Hiroaki Takizawa
Area Doctor and Director of Jiyugaoka Clinic
【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty
Eiko Tanaka
Director of Takatsuki Hospital
【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery
Atsushi Hayashi
Chief Technical Director
【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma
Kanako Misono
Slimming Expert Doctor
【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting
Soichiro Morikawa
Anti-aging treatment expert doctor
【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler
Poster Presentations
Speaker
Job Title
Title
Hiroshi Ohji
ー
Usefulness of preoperative ultrasound examination in submandibular liposuction.
Ayano Okuda
Expert doctor in gynecological plastic surgery
Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~
Go Kanazawa
Director of Hiroshima Clinic and Area Doctor for Hiroshima Area
Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid
Kaito Kuzushima
Ginza Clinic Director Top Expert Doctor in Liposuction
Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】
Aiko Ssasaki
Kawagoe Area Area Doctor and Director of Kawagoe Clinic
Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty
Yuka Takeda
Director of the Esaka Institute
The usefulness of next generation needle Nanosoft Microneedles Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting
Ryuji Tanaka
Hokkaido/Tohoku Area General Manager
Approach to the Management of Lower Eyelid Hollowness with Skin Laxity
Mei Nakayama
ー
Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report
Ayaka Nishikawa
Director of Dermatology Department of Shonan Beauty Group
Fine fiber sheet for application after pico-second laser treatment
Yu Hirata
Director of Okayama Clinic and Area Doctor for Okayama Area
Study on the direction of fat repositioning in transconjunctival blepharoplasty.
Takashi Yamamoto
Director of Nagoya Institute
Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method
Akihiro Yoshida
ー
Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal
About SBC MedicalSBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit https://sbc-holdings.com/
Contacts In Asia: SBC Medical Group Holdings Incorporated Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com In the US: ICR LLC Bill Zima / Managing Partner Email: bill.zima@icrinc.com
Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/136e0459-8d3b-47dd-a2bf-4822ee1cd39bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/89b1bc1d-cf5f-4186-91af-feb0a2f4521bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/4f56644f-8e83-40a3-9e00-aebf919f48edhttps://www.globenewswire.com/NewsRoom/AttachmentNg/128a1a29-7e8d-4e34-b3bc-2e06fab1a6d3
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
ICAI revises tax audit limits for chartered accountants
The Institute of Chartered Accountants of India (ICAI) has announced revised norms for the maximum number of tax audits a chartered accountant can undertake annually. Effective from 1 April 2026, the guidelines aim to enhance audit quality by maintaining the existing limit of 60 tax audits per member per financial year, applicable to both individual and partnership capacities. The revised guidelines specify that the limit of 60 tax audits cannot be distributed or shared among partners in a chartered accountants (CA) company. However, this limit excludes tax audit assignments under clauses (c), (d) and (e) of section 44AB, concerning sections 44AE, 44ADA and 44AD. Additionally, revised tax audit reports will not count towards the 60-audit limit. These changes were decided in ICAI's 442nd and 443rd meetings held on 26–27 May 2025 and 30 June–1 July 2025, respectively. The guidelines aim to ensure that the quality of tax audits remains uncompromised. In a separate development, the ICAI inaugurated the ICAI International ADR Centre (IIAC), a Section 8 company, to promote alternate dispute resolution (ADR) mechanisms in India. The initiative represents ICAI's move into ADR, an area intersecting commercial, legal and economic interests. In a statement, the ICAI said that these centres will enhance the commercial dispute resolution ecosystem by providing a transparent, technology-enabled mechanism. The centres will operate under a governance framework, ensuring integrity, neutrality, and professional excellence for both domestic and international stakeholders. ICAI president Charanjot Singh Nanda said: 'In this evolving business ecosystem, effective dispute resolution is no longer a procedural formality; it is a strategic necessity and IIAC aims to provide this necessity with credibility, neutrality and efficiency, values that are at the core of ICAI's professional ethos. 'The IIAC will serve as a specialised institutional platform offering structured and time-bound arbitration, mediation, conciliation and negotiation services that are professionally managed, process-driven and globally benchmarked.' "ICAI revises tax audit limits for chartered accountants " was originally created and published by The Accountant, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
12 minutes ago
- Yahoo
Nvidia in the Crosshairs: China Just Escalated the AI Chip War
Nvidia (NASDAQ:NVDA) just hit another speed bump in China. Days after the U.S. rolled back export restrictions on its H20 chipdesigned specifically to comply with sanctionsChinese regulators summoned Nvidia to address alleged serious security vulnerabilities. The Cyberspace Administration of China (CAC) raised concerns tied to U.S. lawmakers' comments suggesting these chips may carry location-tracking or shutdown features. The agency demanded internal documentation and clarification from Nvidia's local team. No official details were shared beyond that, but investors are watching closely. The stock gained 2.5% on Germany's Tradegate, supported in part by strong earnings from Microsoft and Meta, but this probe introduces fresh uncertainty. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The timing couldn't be more delicate. CEO Jensen Huang had just wrapped up a high-profile China visit, spotlighting local champions like DeepSeek and Tencent while calling China a global AI powerhouse. Meanwhile, U.S. officials had been framing the H20 green light as a goodwill gesturehoping it would unlock better access to China's rare earths. But now, Chinese regulators are signaling they're not quite sold. Local chipmakers like SMIC and Cambricon popped more than 5% following the CAC's statement, suggesting markets see this as a tailwind for China's self-reliance push. As Forrester's Charlie Dai put it: H20 sales could now face delays, just as China doubles down on homegrown tech. Underneath all this is a bigger chessboard. The U.S. had loosened chip export rules after trade talks in London, and in return, China allowed more outbound flow of rare-earth minerals. But the CAC's sudden scrutiny of the H20 chipespecially one already stripped down to meet U.S. compliancefeels like a move to keep pressure in the trade negotiations. At the same time, domestic players like Huawei are rolling out rivals like the Ascend 910C, which are already being compared to Nvidia's chips for inference workloads. As trade officials sidestep direct comment, one thing is clear: Nvidia's foothold in China remains fragile, and investors will need to watch how this unfoldsone regulatory move at a time. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WIRED
14 minutes ago
- WIRED
Inside the Summit Where China Pitched Its AI Agenda to the World
Jul 31, 2025 11:04 AM Behind closed doors, Chinese researchers are laying the groundwork for a new global AI agenda—without input from the US. Three days after the Trump administration published its much-anticipated AI action plan, the Chinese government put out its own AI policy blueprint. Was the timing a coincidence? I doubt it. China's 'Global AI Governance Action Plan' was released on July 26, the first day of the World Artificial Intelligence Conference (WAIC), the largest annual AI event in China. Geoffrey Hinton and Eric Schmidt were among the many Western tech industry figures who attended the festivities in Shanghai. Our WIRED colleague Will Knight was also on the scene. The vibe at WAIC was the polar opposite of Trump's America-first, regulation-light vision for AI, Will tells me. In his opening speech, Chinese Premier Li Qiang made a sobering case for the importance of global cooperation on AI. He was followed by a series of prominent Chinese AI researchers, who gave technical talks highlighting urgent questions the Trump administration appears to be largely brushing off. Zhou Bowen, leader of the Shanghai AI Lab, one of China's top AI research institutions, touted his team's work on AI safety at WAIC. He also suggested the government could play a role in monitoring commercial AI models for vulnerabilities. In an interview with WIRED, Yi Zeng, a professor at the Chinese Academy of Sciences and one of the country's leading voices on AI, said that he hopes AI safety organizations from around the world find ways to collaborate. 'It would be best if the UK, US, China, Singapore, and other institutes come together,' he said. The conference also included closed-door meetings about AI safety policy issues. Speaking after he attended one such confab, Paul Triolo, a partner at the advisory firm DGA-Albright Stonebridge Group, told WIRED that the discussions had been productive, despite the noticeable absence of American leadership. With the US out of the picture, 'a coalition of major AI safety players, co-led by China, Singapore, the UK, and the EU, will now drive efforts to construct guardrails around frontier AI model development,' Triolo told WIRED. He added that it wasn't just the US government that was missing: Of all the major US AI labs, only Elon Musk's xAI sent employees to attend the WAIC forum. Many Western visitors were surprised to learn how much of the conversation about AI in China revolves around safety regulations. 'You could literally attend AI safety events nonstop in the last seven days. And that was not the case with some of the other global AI summits,' Brian Tse, founder of the Beijing-based AI safety research institute Concordia AI, told me. Earlier this week, Concordia AI hosted a day-long safety forum in Shanghai with famous AI researchers like Stuart Russel and Yoshua Bengio. Switching Positions Comparing China's AI blueprint with Trump's action plan, it appears the two countries have switched positions. When Chinese companies first began developing advanced AI models, many observers thought they would be held back by censorship requirements imposed by the government. Now, US leaders say they want to ensure homegrown AI models 'pursue objective truth,' an endeavor that, as my colleague Steven Levy wrote in last week's Backchannel newsletter, is 'a blatant exercise in top-down ideological bias.' China's AI action plan, meanwhile, reads like a globalist manifesto: It recommends that the United Nations help lead international AI efforts and suggests governments have an important role to play in regulating the technology. Although their governments are very different, when it comes to AI safety, people in China and the US are worried about many of the same things: model hallucinations, discrimination, existential risks, cybersecurity vulnerabilities, etc. Because the US and China are developing frontier AI models 'trained on the same architecture and using the same methods of scaling laws, the types of societal impact and the risks they pose are very, very similar,' says Tse. That also means academic research on AI safety is converging in the two countries, including in areas like scalable oversight (how humans can monitor AI models with other AI models) and the development of interoperable safety testing standards. But Chinese and American leaders have demonstrated they have very different attitudes toward these issues. On one hand, the Trump administration recently tried and failed to put a 10-year moratorium on passing new state-level AI regulations. On the other hand, Chinese officials, including even Xi Jinping himself, are increasingly speaking out about the importance of putting guardrails on AI. Beijing has also been busy drafting domestic standards and rules for the technology, some of which are already in effect. As Trump goes rogue with unorthodox and inconsistent policies, the Chinese government increasingly looks like the adult in the room. With its new AI action plan, Beijing is trying to seize the moment and send the world a message: If you want leadership on this world-changing innovation, look here. Charm Offensive I don't know how effective China's charm offensive will be in the end, but the global retreat of the US does feel like a once-in-a-century opportunity for Beijing to spread its influence, especially at a moment when every country is looking for role models to help them make sense of AI risks and the best ways to manage them. But there's one thing I'm not sure about: How eager will China's domestic AI industry be to embrace this heightened focus on safety? While the Chinese government and academic circles have significantly ramped up their AI safety efforts, industry has so far seemed less enthusiastic—just like in the West. Chinese AI labs disclose less information about their AI safety efforts than their Western counterparts do, according to a recent report published by Concordia AI. Of the 13 frontier AI developers in China the report analyzed, only three produced details about safety assessments in their research publications. Will told me that several tech entrepreneurs he spoke to at WAIC said they were worried about AI risks such as hallucination, model bias, and criminal misuse. But when it came to AGI, many seemed optimistic that the technology will have positive impacts on their life, and they were less concerned about things like job loss or existential risks. Privately, Will says, some entrepreneurs admitted that addressing existential risks isn't as important to them as figuring out how to scale, make money, and beat the competition. But the clear signal from the Chinese government is that companies should be encouraged to tackle AI safety risks, and I wouldn't be surprised if many startups in the country change their tune. Triolo, of DGA-Albright Stonebridge Group, said he expected Chinese frontier research labs to begin publishing more cutting-edge safety work. Some WAIC attendees see China's focus on open source AI as a key part of the picture. 'As Chinese AI companies increasingly open-source powerful AIs, their American counterparts are pressured to do the same,' Bo Peng, a researcher who created the open source large language model RWKV, told WIRED. Peng envisions a future where different nations—including ones that do not always agree—work together on AI. 'A competitive landscape of multiple powerful open-source AIs is in the best interest of AI safety and humanity's future,' he explained. 'Because different AIs naturally embody different values and will keep each other in check.' This is an edition of Zeyi Yang and Louise Matsakis' Made in China newsletter . Read previous newsletters here.
